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ABSTRACT  
Type 2 diabetes mellitus (T2DM) is an independent risk factor for cardiovascular 
(CV) comorbidities, with CV disease being the most common cause of death in 
adults with T2DM. Although glucocentric therapies may improve glycaemic control 
(as determined by glycated haemoglobin levels), evidence suggests that this 
approach alone has limited beneficial effects on CV outcomes relative to 
improvements in lipid and blood pressure control. This may be explained in part by 
the fact that current antidiabetic treatment regimens primarily address overall 
glycaemia and/or fasting plasma glucose, but not the postprandial plasma glucose 
(PPG) excursions that have a fundamental causative role in increasing CV risk. This 
literature review evaluates the relationship between PPG and the risk of CV disease, 
discusses the treatment of T2DM with glucagon-like peptide-1 receptor agonists 
(GLP-1 RAs) and examines the associated CV outcomes. The literature analysis 
suggests that exaggerated PPG excursions are a risk factor for CV disease due to 
their adverse pathophysiologic effects on the vasculature, resulting in increased all-
cause and CV-related mortality. Although GLP-1 RAs are well established in the 
current T2DM treatment paradigm, a subgroup of these compounds have a 
particularly pronounced, persistent and short-lived effect on gastric emptying and, 
hence, lower PPG substantially. However, current long-term data on CV outcomes 
with GLP-1 RAs, are contradictory, with both beneficial and adverse effects having 
been reported. This review explores the opportunity to direct treatment towards 
controlling PPG excursions, thereby improving not only overall glycaemic control but 
also CV outcomes.  
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1 | INTRODUCTION 
Type 2 diabetes mellitus (T2DM) is an independent risk factor for cardiovascular 
(CV) disease, with adults with T2DM two to four times more likely to succumb to CV 
disease or a cerebrovascular event (stroke or a transient ischaemic episode) than 
individuals with normal glucose tolerance.1,2 CV disease remains the most common 
cause of death among adults with T2DM,2 and the concurrence of CV disease in 
patients with T2DM results in a poorer prognosis compared with individuals with CV 
disease alone.2 Hence, a better understanding of the pathophysiology of vascular 
changes that underlie this relationship and how best to address them is likely to 
improve outcomes.  
 Several large studies have evaluated the relationship between glycaemic control 
with different treatment regimens and CV disease in persons with T2DM. The 10-
year follow-up to the United Kingdom Prospective Diabetes Study (UKPDS) found 
that intensive treatment of T2DM with sulphonylurea, insulin or metformin lowered 
the patient’s risk of myocardial infarction (MI) as well as the risks of diabetes-related 
death and all-cause mortality vs conventional therapy (dietary restrictions).3,4 
Individually, most other studies have shown a limited ability of current glucocentric 
therapies to have a discernible and favourable impact on CV disease.5-10 However, a 
meta-analysis of data from the UKPDS, combined with those of three other large 
randomized studies,11 found an overall 9% reduction in the risk of major CV events, 
mostly due to a 15% reduction in MI risk, for more- vs less-intensive glucose-control 
treatment regimens. Furthermore, there was a trend towards reduction in CV disease 
in individuals without previously reported CV events. Another systematic review of 
these same studies found that intensive vs conventional glucose control reduced the 
risk of certain CV outcomes, largely non-fatal MI, but not the risk of CV death or all-
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cause mortality.12 Similarly, a separate meta-analysis of data from these same four 
studies plus one other showed that intensive vs standard glycaemic control 
significantly reduced coronary events, but again with no significant effect on all-
cause mortality. Of note, although these analyses demonstrated that intensive 
glucose therapy and the resulting improved glycaemic control may reduce the risk of 
CV disease, hyperglycaemia is a weaker risk factor for CV disease than cholesterol 
or blood pressure. Hence, the relative impact of reducing hyperglycaemia on CV 
outcomes is less than the adequate control of these other concurrent risk factors.13 
Nevertheless, many studies have implied that postprandial plasma glucose (PPG) is 
a powerful and independent risk factor for CV disease,14 with the development of 
atherosclerosis having been described much earlier in time as a postprandial 
phenomenon.15 Glycaemic control is assessed predominantly using three 
measurements: primarily glycated haemoglobin (HbA1c) and fasting plasma glucose 
(FPG), and rarely PPG. Considering that most individuals spend the majority of the 
day in the postprandial and postabsorptive states (approximately 21 h per day) 
rather than the fasting state (3 h per day, at the end of the night),16 the 
predominance of the PPG state within the daily metabolic cycle makes it an 
important target for the improvement of overall glycaemic control.  
The current T2DM treatment paradigm comprises various drug classes and 
allows for individualization of therapy to control FPG and PPG based on patients’ 
needs, disease characteristics and preferences.17 As part of this paradigm, one class 
of injectable therapy is the glucagon-like peptide-1 receptor agonists (GLP-1 RAs). 
Since the approval of the first of these compounds in 2006, these agents have 
enabled further tailoring of treatment to each patient.18  
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The potential relationship between amplified PPG and CV disease has been a 
focus of research in T2DM for a number of years, and interventional trials have gone 
one step further by trying to control PPG and, as a result, reduce the risk of CV 
events and slow T2DM progression. The present review aims to evaluate the 
relationship between PPG and CV risk, and discuss the effects of treatment with the 
GLP-1 RAs, which appear to reduce CV risk in persons with T2DM. The sodium-
glucose cotransporter-2 (SGLT-2) inhibitors, particularly empagliflozin, also appear 
to lower the CV risk in patients with T2DM.19,20 In contrast, the dipeptidyl peptidase-4 
(DPP-4) inhibitors21 and insulin therapy22 do not affect the risk of CV disease in this 
population. While the CV effects of all of these drug classes warrant detailed 
discussion, the present review will focus on the GLP-1 RAs. 
 
2 | CELLULAR AND VASCULAR EFFECTS OF ELEVATED PPG LEVELS 
In vitro studies have shown that frequent elevations in glucose levels result in 
detrimental effects at the cellular level. High glucose levels for 2 h in isolated hearts, 
and in cultured endothelial cells, induced apoptosis and the formation of 
nitrotyrosine, a marker of oxidative stress that is common in a number of pathologic 
conditions.23,24 Some studies have also shown that intermittent or fluctuating 
exaggerated PPG (defined as rising to above 7.8 mmol/L [140 mg/dL] and/or not 
returning to preprandial levels within 2–3 h25) may be worse than persistent 
hyperglycaemia.26 For example, oscillating high glucose levels when compared with 
stable hyperglycaemia generates more nitrotyrosine and adhesion molecules and 
induces inflammatory cytokines in vitro using cultured human endothelial cells.26 
Fluctuating glucose levels also cause enhanced apoptosis in cultured endothelial 
cells27 and increased mitogenicity in cultured human tubulo-interstitial cells.28  
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 This impact of oscillating glucose concentrations at the cellular level translates to 
changes in vasculature and haemodynamic parameters. The degree of glycaemic 
variability has been shown to be positively related to the levels of oxidative stress 
markers in patients with T2DM.29 Increased glycaemic variability also results in 
endothelial dysfunction with increased levels of nitrotyrosine in persons with and 
without T2DM,30,31 reflecting findings from earlier in vitro studies.23,24  
 In response to acute hyperglycaemia, gene expression relating to free radical 
scavenging (detoxification) is downregulated in human skeletal muscle and adipose 
tissue.32 A study of healthy male volunteers aimed to mimic the blood glycaemic 
parameters of poorly controlled patients with T2DM, and demonstrated that acute 
hyperglycaemia released free radicals, altered baroreflex activity and increased 
blood pressure and heart rate.33 Considered together, these observations support 
the hypothesis that oxidative stress is a major pathophysiologic mechanism 
responsible for the development of CV disease in patients with T2DM.  
 In addition, acute hyperglycaemia in healthy volunteers results in activation of 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB),34 a protein 
complex involved in stress responses that is linked to cancer and inflammatory 
diseases. Several other studies involving persons with diabetes have shown that 
hyperglycaemia can activate the transcription of NF-κB-regulated inflammatory 
genes.35 
 In a cross-sectional study of 232 Japanese patients with T2DM, exaggerated 
PPG excursions were independently correlated with the presence of 
microangiopathy in the form of diabetic retinopathy and neuropathy.36 Moreover, 
development and progression of macrovascular disease and atherosclerosis and, 
indeed, the 2-h PPG level, have been found to be a significant determinant of carotid 
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intima-media thickness (CIMT; a measure of atherosclerosis) and shown to be more 
closely correlated with CIMT than FPG in patients with T2DM and in subjects with 
normal glucose tolerance.37 Exaggerated PPG excursions reportedly also decrease 
vasodilation,38 resulting in an increase in the sheer force on the vascular 
endothelium due to reduced blood flow and increased blood pressure. 
 
3 | EXAGGERATED PPG: AN INDEPENDENT RISK FACTOR FOR CV DISEASE 
AND ALL-CAUSE AND CV-RELATED MORTALITY  
Endothelial dysfunction (including reduced vasodilation) and increased oxidative 
stress predict CV events in patients with documented CV disease.39 Table 1 
summarizes the findings of several observational studies that demonstrated the 
association between PPG and the development of CV disease in non-diabetic 
subjects and patients with T2DM. Moreover, these studies have indicated that a high 
PPG level is also an independent predictor of all-cause mortality and death due to 
CV disease. This finding appears to be consistent across both sexes and across 
multiple races. 
 
4 | POTENTIAL FOR REDUCING CV EVENTS BY CONTROLLING PPG 
EXCURSIONS 
Despite the evidence for an association between PPG and CV risk, reports on the 
possible effects of treatment that lower PPG on CV outcomes are inconclusive and 
conflicting. In subjects with impaired glucose tolerance, treatment with acarbose 
slowed the progression of CIMT reduction compared with placebo.40 Furthermore, 
treatment with meglitinides, a class of short-acting oral antidiabetics that increases 
insulin secretion in a similar manner to sulphonylureas and addresses mainly PPG 
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control,41,42 caused regression of CIMT. All together, these and other data indicate 
that addressing PPG excursions may have a protective effect against CV 
disease.40,43,44 In support of this, postchallenge plasma glucose and spikes have 
been shown to be more strongly associated with CIMT than FPG and HbA1c.45 
 However, results of interventional studies that have attempted to control PPG 
utilizing different therapeutic strategies to improve CV outcomes have been 
inconsistent. On the one hand, two studies, the STOP-NIDDM trial and the MEta-
analysis of Risk Improvement under Acarbose (MERIA) meta-analysis, showed that 
administration of acarbose to address PPG excursions in patients with T2DM and in 
subjects with impaired glucose tolerance significantly reduced the risk of CV events, 
including MI.46 Furthermore, a study of Japanese patients with T2DM revealed that 
thrice-daily bolus insulin resulted in significantly (p < 0.05) slower progression of 
diabetic microvascular complications compared with a basal insulin regimen.47 
 On the other hand, the Nateglinide And Valsartan in Impaired Glucose Tolerance 
Outcomes Research (NAVIGATOR) study, a 5-year randomized, placebo-controlled 
trial of nateglinide, a drug belonging to the aforementioned meglitinides class, in 
subjects with impaired glucose tolerance and evident CV disease and/or the 
presence of CV risk factors, reported that active treatment did not reduce CV and 
diabetes risk.48 These results may be explained by the fact that in this trial 
nateglinide seems to have been inefficient and unable to improve glucose tolerance. 
The Hyperglycemia and its Effect After Acute Myocardial Infarction on 
Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (HEART2D) 
study investigated the use of basal or thrice-daily bolus insulin to control FPG or 
PPG, respectively, in patients with T2DM who had experienced an acute MI.49 As 
PPG excursions were improved in patients treated with prandial insulin compared 
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with those receiving basal insulin only, and total glucose exposure was similarly 
improved in both arms,49 one would expect the incidence of CV events to have been 
lower in the prandial vs basal insulin group. However, the risk of CV events was not 
reduced in either treatment group and, as a result, the study was halted 
prematurely.49 A subsequent post hoc analysis of this study did show a beneficial 
effect of reducing PPG on CV risk in older people.50 A feasible explanation for the 
lack of difference between the two treatment groups in the original HEART2D study 
may be the fact that both groups were treated with insulin, with insulin itself exerting 
a powerful inhibitory effect on activation of oxidative stress.51,52 
 
5 | THE ROLE OF GLP-1 RAS IN THE CONTROL OF PPG 
In recent years, incretin-based therapies have been introduced in the management 
of T2DM. Two distinct drug classes are currently approved: GLP-1 RAs and DPP-4 
inhibitors. GLP-1 RAs mimic the actions of, and are more resistant to, degradation 
than native GLP-1, while DPP-4 inhibitors work by inhibiting the degradation of 
native GLP-1. Members of both of the incretin group of preparations have been 
extensively shown to improve glycaemic control.53 Based on the pharmacodynamic 
and pharmacokinetic differences between the GLP-1 RAs, they can be divided into 
two main groups according to their predominant impact on either PPG, i.e. prandial 
(short acting), or FPG, i.e. non-prandial (long acting). Currently, a total of six GLP-1 
RAs has been approved for the treatment of T2DM: two prandial GLP-1 RAs 
(exenatide twice daily and lixisenatide once daily) and four long-acting preparations 
(liraglutide once daily, albiglutide once weekly, dulaglutide once weekly, exenatide 
long-acting release [once daily]). A summary of the differences between the two 
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groups in terms of their mechanisms of action and their precise effects on glycaemic 
control is shown in Table 2. 
 A recent head-to-head comparison54 assessed the effects on PPG and gastric 
emptying of two GLP-1 RAs, short-acting lixisenatide and long-acting liraglutide. As 
expected, based on previous reports that the predominant effect of lixisenatide is to 
delay gastric emptying, leading to reduced glucose reabsorption and subsequent 
reductions in PPG,55,56 lixisenatide achieved greater reductions than liraglutide in 
both area under the curve PPG0030–0430 h and gastric emptying (p < 0.001 for both, for 
lixisenatide vs liraglutide). Surprisingly, FPG was unchanged for both treatments. 
This study also evaluated 24-h heart rate, and showed differences between the two 
short- and long-acting agents.54 
 
6 | ACCELERATED HEART RATE WITH GLP-1 RAS AND ASSOCIATED RISK 
Current literature suggests that an increase in heart rate of 10 bpm leads to at least 
a 20% higher risk of cardiac death, and that this elevated CV risk is similar to that 
associated with a 10 mmHg increase in systolic blood pressure.57 A large 
prospective cohort study has shown that an elevated resting heart rate (RHR) is a 
strong risk factor for the development of fatal MI; compared with a RHR of <60 bpm, 
a RHR of >90 bpm is associated with a two- and threefold higher risk of CV death in 
men and women, respectively.58 Also, in a study involving patients with T2DM with a 
high RHR, there was a greater incidence or progression of nephropathy and 
retinopathy,59 and an increased risk of all-cause mortality, CV death and major CV 
outcomes.60 
 As noted above, published data indicate that GLP-1 RAs can influence heart 
rate, although the extent of this increase varies between medications. A recent 
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analysis assessing the impact of lixisenatide, exenatide, liraglutide, albiglutide, 
exenatide long-acting release and dulaglutide on heart rate showed that, in patients 
with T2DM, prandial GLP-1 RAs led to a modest and transient increase in mean 24-h 
heart rate, whereas the long-acting GLP-1 RAs caused a more profound increase.61 
When patients with T2DM were further assessed using 24-h ambulatory heart rate 
monitoring, 8 weeks of treatment with liraglutide (1.2 or 1.8 mg) resulted in a 
clinically significant increase in 24-h mean heart rate of 9 bpm (p < 0.0001 vs 
baseline) compared with an increase of 3 bpm with lixisenatide 20 µg.54 Moreover, 
the increase in heart rate with liraglutide was predominantly at night, abolishing the 
normal circadian rhythm in heart rate, which is reduced overnight. In a manner 
similar to lixisenatide, exenatide twice daily resulted in an insignificant 2 bpm 
increase in 24-h mean heart rate in a 12-week interventional study, and also 
maintained the natural circadian rhythm in heart rate.62 Hence, some evidence 
suggests that any potentially adverse increases in heart rate appear to be limited to 
the long-acting GLP-1 RAs. The precise mechanism by which these drugs affect 
heart rate is unknown, although a study employing a murine model found that the 
GLP-1 receptor is central in the control of heart rate.63  
 
7 | CV OUTCOMES WITH GLP-1 RAS 
As detailed in section 4 above, some studies40-47 demonstrate a link between high 
PPG levels and CV outcomes, and show that controlling PPG can have CV benefits, 
while other studies48,49 are contradictory. Should such an association be confirmed, it 
seems plausible that GLP-1 RAs may have CV benefits, especially the short-acting 
preparations. It has been suggested that lixisenatide may have potential cardio-
protective effects as, in isolated murine hearts subjected to acute ischaemia and 
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reperfusion, lixisenatide reduced infarct size and improved cardiac function.64 
Furthermore, in the Phase III GetGoal clinical trial programme for lixisenatide, 
improvements in hypertension were also reported for some patients in the 
lixisenatide treatment arms.65 As hypertension is a strong risk factor for CV disease, 
lowering hypertension rates associated with hyperglycemia in general,33 and 
elevated PPG in particular,38 may contribute indirectly to the reduction of overall CV 
risk by GLP-1 RAs.  
 Similarly, exenatide may also have CV benefits. In pigs treated with either 
exenatide or saline, exenatide reduced MI size and prevented deterioration of 
systolic and diastolic cardiac function (including systolic wall thickening and 
myocardial stiffness).66 Similarly, both native exendin-467-69 and an exenatide 
analogue70 have been shown to have direct beneficial effects on cardiac function in 
murine models, including preservation of myocardial performance and protection 
against cardiac remodelling, suggesting that GLP-1 RAs have cardioprotective 
effects. GLP-1 RAs have demonstrated their ability to preserve or improve 
myocardial function during recovery following acute myocardial ischaemia. 
Suggested mechanisms for this benefit include attenuation of adverse cardiac 
remodelling (interstitial fibrosis and cardiac hypertrophy) mediated via reduced 
oxidative stress-induced injury,67 improved metabolic, blood flow or neural 
transmission71 and/or a reduced inflammatory and extracellular matrix response.68,69 
Moreover, in patients with ST-segment elevation MI, adjunctive exenatide to primary 
coronary intervention was associated with a reduction in infarct size and 
improvement in subclinical left ventricular function.72 Contrarily, the FLuctuATion 
reduction with inSUlin and Glp-1 Added together (FLAT-SUGAR) trial, assessing 
glucose variability in a 26-week randomized comparison of basal insulin plus twice-
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daily exenatide vs basal-bolus insulin in patients with T2DM at high CV risk, did not 
show any CV benefits of exenatide.73 Although patients receiving basal insulin-
exenatide treatment presented with reduced glucose variability, lower body weight, 
and a reduction in the levels of alanine aminotransferase and serum amyloid, while 
also maintaining equivalent HbA1c levels compared with those receiving basal-bolus 
insulin treatment, there was no statistically significant improvement in other CV risk 
biomarkers. Surprisingly, levels of urinary 8-iso PGF2α (a reliable biomarker of 
activation of oxidative stress) were improved markedly in the basal-bolus insulin 
treatment group. This unexpected result can be explained by the fact that patients in 
both treatment arms were treated with insulin, and that, as mentioned previously, 
exogeneous insulin exerts an inhibitory effect on oxidative stress.52,74 Of note, 
positive CV effects were observed in the recent DURATION-8 trial, which assessed 
the efficacy and safety of co-initiation of exenatide and the SGLT-2 inhibitor 
dapagliflozin vs exenatide or dapagliflozin alone in patients with T2DM inadequately 
controlled on metformin. The combination of exenatide with dapagliflozin significantly 
improved CV risk factors (e.g. reduction in systolic blood pressure) compared with 
either drug alone.75 
 Long-acting GLP-1 RAs in animal studies have also demonstrated CV benefits. 
With liraglutide twice daily for 7 days and following the induction of MI, survival was 
significantly higher in liraglutide-treated mice vs those injected with saline.76 
Furthermore, liraglutide was also seen to reduce cardiac rupture, infarct size and 
improved cardiac output.76 However, the Functional Impact of GLP-1 for Heart 
Failure Treatment (FIGHT) study showed that liraglutide vs placebo treatment was 
not associated with improved clinical stability following hospitalization in subjects 
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with advanced heart failure and reduced left ventricular ejection fraction both with 
and without diabetes.77 
 Since 2008, regulatory agencies require that all therapies for diabetes are 
assessed in a CV outcomes trial (CVOT) to ensure CV safety in order to grant and 
sustain approval.78 Currently, several CVOTs are ongoing for already approved GLP-
1 RAs, including Exenatide Study of Cardiovascular Event Lowering (EXSCEL) for 
exenatide long-acting release, Researching CV Events with a Weekly Incretin in 
Diabetes (REWIND) for dulaglutide, and HARMONY Outcomes for albiglutide, and 
are due to be completed in 2018/19 (Table 3). The recently completed SUSTAINTM-6 
CVOT for semaglutide, a GLP-1 analogue currently in development for treating 
T2DM, showed that the primary composite endpoint (first occurrence of CV death, 
non-fatal MI or non-fatal stroke) occurred in 6.6% of patients receiving semaglutide 
vs 8.9% in the placebo group (hazard ratio [HR] 0.74; 95% confidence interval [CI] 
0.58, 0.95; p < 0.001 for non-inferiority).79  
The Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial 
assessed CV outcomes in patients with T2DM and acute coronary syndrome being 
treated with lixisenatide80,81 and was completed in February 2015. A total of 6068 
patients were randomized and followed for a median of 25 months. A primary 
endpoint event (first occurrence of either death from CV causes, non-fatal MI, non-
fatal stroke or hospitalization for unstable angina) occurred in 13.4% of patients on 
lixisenatide vs 13.2% in the placebo group (HR 1.02; 95% CI 0.89, 1.17). This 
showed that lixisenatide was non-inferior to placebo (p < 0.001) but was not superior 
(p = 0.81). There were no differences in the rates of hospitalizations for heart failure 
or rate of death between the lixisenatide and placebo groups. Overall, the study 
showed that the addition of once-daily lixisenatide to the antidiabetic treatment 
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regimen did not significantly impact on the rate of major CV events or other related 
serious adverse events in patients with acute coronary syndrome. Therefore, noting 
the specifics of the patient population and the trial design, the results of ELIXA do 
not directly support the theory proposed elsewhere in this review regarding the 
potential to affect CV outcomes via control of PPG. 
 In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular 
Outcome Results (LEADER) study, which was completed in December 2015, a total 
of 9340 people with T2DM were randomized to either liraglutide or placebo for 3.5–5 
years (median follow-up of 3.8 years). The trial’s primary endpoint was the composite 
outcome of the first occurrence of either CV death, non-fatal MI or non-fatal stroke, 
and occurred in 13.0% vs 14.9% of patients, respectively (HR 0.87; 95% CI 0.78, 
0.97; p < 0.001 for non-inferiority, p = 0.01 for superiority).19 Furthermore, fewer 
patients died from CV causes (4.7% vs 6.0%, respectively; HR 0.78; 95% CI 0.66, 
0.93; p = 0.007) and any cause (8.2% vs 9.6%, respectively; HR 0.85; 95% CI 0.74, 
0.97; p = 0.02). Moreover, the rates of non-fatal MI, non-fatal stroke and 
hospitalization for heart failure were also non-significantly lower for liraglutide vs 
placebo. These results show that liraglutide can lower the risk of major adverse CV 
events compared with placebo. However, when analysing subgroups of patients 
stratified according to other antidiabetic therapies administered alongside liraglutide, 
the reduction in CV events was shown to be significant only in those patients 
receiving a single oral antidiabetic drug (OAD). This observation could potentially 
indicate that the significant reduction observed in the overall population may result 
mainly from the improvement seen in this particular subgroup, and that the beneficial 
effect of liraglutide on CV risk is less robust when patients are also treated with 
insulin and/or more than one OAD alongside liraglutide. 
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 Although both of these CVOTs for these two currently available GLP-1 RAs 
were broadly similar in terms of their overall design, there are major differences 
between them. While in ELIXA only patients who were within 180 days post-acute 
coronary event and, hence, at the highest risk of a further CV event, were eligible for 
enrolment, in LEADER, patients with a pre-existing CV condition or with high risk for 
CV disease were included, corresponding to a more chronic CV risk status. 
Furthermore, ELIXA had a shorter median follow-up of 2.1 years compared with 3.8 
years in LEADER, and also in ELIXA the primary composite endpoint comprised the 
first occurrence of four individual endpoints (death from CV causes, non-fatal MI, 
non-fatal stroke or hospitalization for unstable angina), while in LEADER only three 
endpoints were included (CV death, non-fatal MI or non-fatal stroke). Of note, other 
baseline characteristics including T2DM duration (mean [standard deviation] of 9.3 
[8.3] years and 12.7 [8.0] years for ELIXA and LEADER, respectively) and HbA1c 
(mean [standard deviation] of 7.7 [1.3]% and 8.7 [1.5]% for ELIXA and LEADER, 
respectively) were also distinct between the two studies. As all of these differences 
between the two studies80,82 may have impacted the overall results, comparisons 
between ELIXA and LEADER must be made with caution. Furthermore, the 
differences between the mechanisms of action of the short- and long-acting GLP-1 
RAs should also be taken into account: Whereas the short-acting agent lixisenatide 
acts primarily by acutely lowering postprandial glucose excursions, the longer-acting 
agent liraglutide predominantly reduces the fasting glucose.18 Thereby, differences in 
daily glycaemic variability between these two GLP-1 RAs may possibly have 
contributed to the different CV outcomes observed in the ELIXA and LEADER 
studies. Similarly, although not focused upon here, as semaglutide is an 
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investigational compound, any direct comparisons with SUSTAIN-6 CVOT79 should 
also be made with care. 
 Owing to these recently published and ongoing CVOTs in diabetes, the 
Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group has been 
established. In their first summit meeting in 2015, the group noted the importance of 
distinguishing between CVOTs with a primary focus on the CV safety of novel drugs 
vs those that truly aim to assess the potential reduction of CV events.83 Notably, the 
former trial type is characterized by a study design that includes high-risk patients 
with T2DM, such as those included in ELIXA, and similar glycaemic control between 
active and standard treatment groups. Additionally, the group discussed whether the 
results observed to date are tranferable to wider patient groups. In brief, in cases of 
neutrality such as ELIXA, results could be extrapolated to patients with T2DM and a 
lower CV risk; however, in the event of CV reductions, as in LEADER, results should 
not be translated beyond the study group examined.83  
 While the clinical studies of CV outcomes in patients treated with GLP-1 RAs 
appear to demonstrate a cardioprotective function of these drugs, the precise 
mechanism behind this effect remains elusive. Aside from the possible link between 
glucose elevation and control, other factors may be involved. As the GLP-1 receptor 
is expressed widely throughout the body, including in the myocardium, the 
cardioprotective effects on GLP-1 RAs may, in part, result from direct action in the 
heart and through indirect actions involving GLP-1 signalling in vascular cells and 
other peripheral tissues.71 
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8 | CONCLUDING REMARKS 
Our analysis of current literature suggests that poor glycaemic control and especially 
excessive glycaemic excursions predominantly after meals (PPG) may increase the 
risk of CV disease in patients with T2DM and individuals with normal glucose 
tolerance.84-92 However, the relationship between postprandial glucose 
hyperglycaemia and CV outcomes is complex, with additional research needed to 
characterize this association further.  
 In order to achieve HbA1c targets in patients with T2DM, individualized 
treatment that controls both PPG and FPG may be the best option,93 with 
antidiabetic medications that control PPG being of particular interest due to the role 
of PPG excursions in the pathophysiology of CV disease. In order to maintain a 
patient-centred, individualized approach to treatment, the respective distribution of 
postprandial and basal therapies should be modulated according to each patient’s 
24-h glycaemic profile. While this procedure is usually recommended for choosing 
the optimum pre-meal time at which boluses of rapid-acting insulin should be 
injected during the implementation of a basal-plus insulin regimen, we believe that it 
is useful for a similar system to be implemented for treatment regimens involving 
basal insulin plus a short-acting GLP-1 RA, such as lixisenatide. 
 As discussed, the approved GLP-1 RAs have varying effects; some specifically 
control PPG, others target FPG (Table 2). Hence, the use of prandial GLP-1 RAs in 
combination with therapies that control FPG may provide benefits owing to a greater 
likelihood of achieving HbA1c targets even in advanced T2DM. ELIXA, a CVOT 
assessing lixisenatide, has shown that lixisenatide does not pose a CV risk,81 while 
data from LEADER suggest that liraglutide may have beneficial effects on the risk of 
CV events.19 The lack of a detectable lowering of CV risk in ELIXA appears to 
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weaken the argument that CV benefits can be achieved through lowering PPG. 
However, in this study lixisenatide was administered only before breakfast, and while 
the PPG-lowering effect may have persisted to other meals (as has been 
demonstrated previously94), the predominant effect would have been after breakfast. 
This raises the question as to whether a CV benefit would be seen were a short-
acting GLP-1 RA administered more than once daily. It is important to note that this 
is not a licensed regimen, but could be an interesting concept to explore in a clinical 
trial setting. While the completion of ongoing CVOTs will provide further insight on 
the risk/benefit of individualized treatment with GLP-1 analogues, a recent 
publication95 has suggested that, based on results from completed CVOTs, which 
have not demonstrated a CV risk for the various compounds assessed, there is a 
need to reassess the Food and Drug Administration’s requirement for a CVOT for 
every new antihyperglycaemic agent. The authors suggest that a more individualized 
approach may be justified. 
 In conclusion, exaggerated PPG excursions appear to have a fundamental 
causative role in the relationship between T2DM and increased CV risk. This finding 
presents an opportunity to direct treatment towards also controlling PPG excursions 
to improve both glycaemic control and also CV outcomes.  
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TABLE 1 Reported risk of CV events with PPG excursions in observational studies 
in either the general population or patients with T2DM 
General population studies 
Study first author 
and citation 
Study type Study findings 
de Vegt et al. 
(1999)86  
Hoorn study: an 8-year follow-up 
of a population-based cohort of 
more than 2300 older (50–75 
years) subjects 
All-cause and CV mortality were 
predicted by increased 2-h PPG 
Balkau et al. 
(1998)84 
20-year follow-up to the 
Whitehall Study, the Paris 
Prospective Study and the 
Helsinki Policemen Study 
comprising >17,000 males 
Men with higher 2-h PPG 
excursions had an increased risk of 
all-cause and CV mortality 
compared with individuals in lower 
percentiles of the 2-h PPG 
distribution 
Lowe et al. 
(1997)91 
Analysis of white (n = 11,554) 
and African–American (n = 666) 
men (35–64 years) in the 
Chicago Heart Association 
Detection Project in Industry 
Study 
Relative risk of all-cause and CV 
mortality was increased in those 
subjects with asymptomatic post-
load hyperglycaemia compared with 
those with normal post-load glucose 
levels 
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Donahue et al. 
(1987)88 
Honolulu Heart Program: 12-
year study of more than 8000 
men aged 45–70 years of 
Japanese ancestry 
Based on a subset of 6394 non-
diabetic subjects, those with the 
most extreme PPG excursions 1 h 
after a 50 g glucose challenge had 
a significantly increased risk of fatal 
coronary disease compared with 
individuals with lower PPG 
excursions 
Nakagami (2004)92 
Analysis of five studies of a total 
of more than 6800 subjects of 
Japanese and Asian Indian 
origin 
Elevated 2-h PPG increased the 
risk of all-cause and CV mortality 
Patients with impaired glucose tolerance and T2DM 
Study first author 
and citation 
Study type Study findings 
DECODE Study 
Group (1999)87 
DECODE: a study of 13 
prospective European cohort 
studies, including more 
than18,000 men and 7300 
women with impaired glucose 
tolerance 
Subjects with greater 2-h PPG 
excursions had an increased risk of 
death compared with individuals 
with less extreme PPG excursions 
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Chiasson et al. 
(2002)96 
Chiasson et al. 
(2003)46 
STOP-NIDDM: a study of 
approximately 1400 subjects 
comparing acarbose vs placebo 
Acarbose not only reduced the 
progression from impaired glucose 
tolerance to T2DM, but was also 
associated with a reduction in CV 
events 
Coutinho et al. 
(1999)97 
A meta-regression comprising 
almost 100,000 subjects 
Increased 2-h PPG levels were 
associated with a greater risk of CV 
events in subjects with normal 
glucose tolerance and also 
individuals with glucose values 
within the diabetic range 
Hanefeld et al. 
(1996)89 
Diabetes Intervention Study: a 
prospective study of 
approximately 1100 patients 
with T2DM 
Multivariate analysis revealed that 
PPG was an independent risk factor 
for death with subjects with PPG 
>10 mmol/L 1 h after breakfast 
having a 40% greater relative risk of 
MI than those with PPG ≤8 mmol/L 
Cavalot et al. 
(2006)85 
A 5-year follow-up study of 529 
patients with T2DM 
PPG but not FPG was found to be 
an independent risk factor for CV 
events, particularly in women 
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Jackson et al. 
(1992)90 
The Islington Diabetes Survey: a 
study of 223 patients with T2DM 
2-h PPG after an oral glucose 
tolerance test was a better predictor 
of CV disease (including angina, 
MI, or ischaemia) than HbA1c 
CV, cardiovascular; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; MI, 
myocardial infarction; PPG, postprandial plasma glucose; T2DM, type 2 diabetes 
mellitus.  
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TABLE 2 Comparison of prandial (short-) vs long-acting GLP-1 RAs18 
Parameters Short-acting GLP-1 RAs Long-acting GLP-1 RAs 
Compounds 
 
 
Exenatide 
Lixisenatide 
Albiglutide 
Dulaglutide 
Exenatide LAR 
Liraglutide 
Half-life 2–5 h 12 h – several days 
Effects 
Fasting blood glucose 
levels 
Modest reduction  Strong reduction 
Postprandial 
hyperglycaemia 
Strong reduction Modest reduction 
Fasting insulin secretion Modest stimulation Strong stimulation 
Postprandial insulin 
secretion 
Reduction Modest stimulation 
Glucagon secretion Reduction Reduction 
Gastric-emptying rate Deceleration No effect 
Blood pressure Reduction Reduction 
Heart rate No effect or small increase 
(0–2 bpm) 
Moderate increase (2–5 
bpm) 
Body weight reduction 1–5 kg 2–5 kg 
Induction of nausea 20–50%, attenuates slowly 
(weeks to many months) 
20–40%, attenuates quickly 
(~4–8 weeks) 
GLP-1 RA, glucagon-like peptide-1 receptor agonist; LAR, long-acting release. 
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TABLE 3 Currently ongoing CVOTs for GLP-1 RAs 
Trial name  
(ClinicalTrials.gov 
Identifier) 
Drug 
Planned patient 
number 
Expected 
completion date 
EXSCEL  
(NCT01144338) 
Exenatide 
14,000 April 2018 
ITCA 650 
(NCT01455896) 
4000 July 2018 
REWIND 
(NCT01394952) 
Dulaglutide 9622 July 2018 
HARMONY Outcomes 
(NCT02465515) 
Albiglutide 9400 May 2019 
CVOT, cardiovascular outcomes trial; GLP-1 RA, glucagon-like peptide-1 receptor 
agonist. 
